List of Excipients in Branded Drug METADATE CD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company LLC	METADATE CD	methylphenidate hydrochloride	0527-6579	DIBUTYL SEBACATE
Lannett Company LLC	METADATE CD	methylphenidate hydrochloride	0527-6579	FD&C BLUE NO. 2
Lannett Company LLC	METADATE CD	methylphenidate hydrochloride	0527-6579	FERRIC OXIDE YELLOW

METADATE CD Excipient Strategy, Formulation Economics, and Commercial Opportunities

Last updated: August 26, 2026

Metadate CD is a once-daily extended-release methylphenidate hydrochloride capsule built around multiparticulate bead technology. Its commercial value depends less on a novel active ingredient than on reliable biphasic release, pediatric usability, dose flexibility, supply continuity, and regulatory equivalence. The principal opportunities are generic or differentiated methylphenidate ER capsules, alternative sprinkle systems, coating and bead-platform licensing, and supply agreements for critical excipients.

What is Metadate CD and how does its release system work?

Metadate CD contains methylphenidate hydrochloride in an extended-release capsule with immediate-release and controlled-release bead populations. The product delivers approximately 30% of the dose immediately and 70% through extended release, according to the prescribing information.[1]

Attribute	Metadate CD profile
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release capsule
Strengths	10, 20, 30, 40, 50, and 60 mg
Release design	Approximately 30% immediate release and 70% extended release
Administration	Once daily, generally in the morning
Pediatric use	ADHD patients age 6 and older
Sprinkle option	Capsule contents may be sprinkled on applesauce and swallowed without chewing
Regulatory category	Prescription Schedule II stimulant
FDA approval	Original approval in 2001
Therapeutic class	CNS stimulant for attention-deficit/hyperactivity disorder

The bead system separates the initial dose from the sustained dose. That architecture creates formulation sensitivity: changes to coating thickness, polymer grade, plasticizer concentration, bead size, or dissolution conditions can alter both early exposure and late-day coverage.

What excipients are used in Metadate CD?

Metadate CD uses excipients associated with multiparticulate manufacturing, polymer coating, capsule production, and product identification. Public labeling identifies excipient categories and specific inactive ingredients, although exact quantities and processing parameters are proprietary.[1,2]

Core excipient functions

Excipient function	Typical role in a Metadate CD-type system	Commercial relevance
Inert bead substrate	Provides the surface for drug layering and polymer coating	Requires uniform particle-size distribution
Binder	Promotes adhesion of methylphenidate to the substrate	Affects coating defects and dose uniformity
Controlled-release polymer	Regulates water penetration and drug diffusion	The highest-value formulation variable
Pore former or surfactant	Adjusts permeability and wetting	Can shift dissolution across strengths
Plasticizer	Prevents brittle polymer films	Critical to coating integrity and storage stability
Anti-tacking agent	Prevents bead agglomeration during coating	Important for high-throughput production
Capsule shell	Delivers the multiparticulate dose	Supports color coding and dose identification
Opacifier and colorant	Provides appearance and strength differentiation	Supports medication adherence and error reduction
Lubricant or glidant	Improves powder and capsule processing	Affects encapsulation efficiency

Labeling for Metadate CD identifies ingredients including gelatin, sucrose, povidone, ethylcellulose, hypromellose, talc, titanium dioxide, and colorants. Depending on strength and capsule presentation, the color system may include iron oxides or approved synthetic dyes.[1,2]

The formulation strategy should treat excipients as a functional system rather than as interchangeable ingredients. A substitution that preserves nominal composition but changes polymer viscosity, particle morphology, residual moisture, or coating permeability can change the product’s pharmacokinetic profile.

Which excipients create the strongest commercial opportunities?

The most attractive opportunities are excipients and services that improve release reproducibility, manufacturing throughput, patient acceptability, or regulatory comparability.

Controlled-release polymers

Ethylcellulose and related aqueous or organic polymer systems are central to diffusion-controlled release. Suppliers can differentiate through:

• Narrow viscosity and particle-size specifications.
• Low residual solvent and low moisture profiles.
• Consistent permeability after curing.
• Ready-to-use coating dispersions.
• Documentation supporting pharmaceutical equivalence and change control.

A polymer supplier with historical use in an approved methylphenidate multiparticulate product may have an advantage in customer qualification, even when the material is not protected by a composition patent.

Plasticizers and coating additives

Plasticizers such as dibutyl sebacate, triethyl citrate, or comparable materials influence film flexibility and permeability. Commercial value comes from controlling:

• Film cracking during storage.
• Bead sticking during fluid-bed coating.
• Release drift after aging.
• Compatibility with the active ingredient and substrate.
• Scale-up from pilot coating to commercial batch sizes.

Coating-process development is often a larger barrier than the purchase price of the excipient. Suppliers that provide formulation-ready systems, process parameters, and technical support can capture higher margins than commodity excipient vendors.

Functional bead substrates

Sugar spheres or other inert cores must meet tight specifications for size, friability, surface area, and density. A narrow substrate distribution reduces dose variability and improves coating uniformity.

Potential commercial products include:

• High-uniformity starter pellets.
• Low-friability bead substrates.
• Directly compressible or capsule-compatible multiparticulates.
• Drug-layering platforms suitable for methylphenidate and other CNS drugs.

Capsule and sprinkle-system components

Metadate CD’s sprinkle administration is commercially important for pediatric patients who have difficulty swallowing capsules. Opportunities include:

• Easier-opening child-resistant packaging.
• Taste-masked beads.
• Lower-friction capsule shells.
• Capsule-in-capsule systems.
• Sprinkle-compatible formulations with improved mouthfeel.
• Unit-dose packaging for schools and caregivers.

The product must retain the “do not chew” performance requirement. Bead fracture can convert a controlled-release system into a faster-release dose and may create safety or bioequivalence problems.[1]

What formulation patents protect Metadate CD?

The original commercial protection for Metadate CD was based on multiparticulate methylphenidate technology, formulation know-how, regulatory exclusivity, and product-specific manufacturing controls. The relevant patent estate is materially weaker today than during the original launch period because the product was approved in 2001 and the ordinary small-molecule exclusivity period has expired.

Current intellectual-property position

IP category	Strategic assessment
Active ingredient patents	Not commercially relevant for methylphenidate hydrochloride
Original formulation patents	Historical importance; likely expired or near the end of enforceable life depending on patent and patent-term adjustment
Method-of-use patents	Potentially relevant only if specifically listed and unexpired
Manufacturing know-how	Remains commercially important but is generally protected as trade secret
Excipient composition	Usually difficult to protect broadly unless tied to measurable release or stability parameters
Orange Book patents	Must be checked against the current FDA Orange Book listing for the exact product and holder
Generic challenges	Primarily ANDA-based pharmaceutical-equivalence and bioequivalence competition

A definitive patent opinion requires a current Orange Book review, patent-family analysis, terminal-disclaimer review, and litigation search. Historic patents should not be treated as current barriers without confirming expiration and listing status in FDA records.[3]

When does Metadate CD lose exclusivity?

Metadate CD’s FDA approval in 2001 means its five-year new chemical entity exclusivity expired no later than 2006, assuming the approval was treated under the standard NCE framework.[3,4] Any remaining commercial protection would have depended on formulation patents, method-of-use patents, pediatric exclusivity, regulatory requirements, or manufacturing complexity.

The product is therefore exposed to generic competition. Methylphenidate ER capsule products using bead-based systems have entered the U.S. market, and several manufacturers compete across strengths and distribution channels.

Exclusivity mechanism	Metadate CD relevance
Five-year NCE exclusivity	Expired
Three-year new clinical investigation exclusivity	Not a continuing barrier
Pediatric exclusivity	Any original extension has expired
Orphan exclusivity	Not applicable to ADHD use
Patent exclusivity	Requires current patent-by-patent verification
REMS-based barrier	No product-specific REMS barrier is the principal commercial issue
Controlled-substance controls	Apply to all methylphenidate products and affect distribution

What is the Orange Book and Paragraph IV status of Metadate CD?

Metadate CD is a small-molecule product regulated through the ANDA pathway rather than the biosimilar pathway. Generic applicants may certify against listed patents under Paragraph I, II, III, or IV certifications. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed.[3]

The business significance of Paragraph IV activity depends on whether an unexpired patent is listed for the reference product. If the current Orange Book contains no enforceable formulation or method-of-use patent that blocks approval, the principal competition risk shifts from patent litigation to technical approval, manufacturing capacity, controlled-substance supply, and payer substitution.

Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence. For an extended-release methylphenidate product, regulators can scrutinize:

• Dose proportionality across strengths.
• Fed and fasting pharmacokinetics.
• Early exposure from the immediate-release fraction.
• Late exposure from the controlled-release fraction.
• In-vitro dissolution across multiple media and time points.
• Alcohol-induced release changes.
• Sprinkle administration performance.
• Stability and uniformity across bead populations.

What regulatory barriers affect a Metadate CD generic?

The principal regulatory pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. An applicant must match the reference listed drug in active ingredient, dosage form, strength, route of administration, and labeling, subject to permitted differences.[3]

The most important technical risk is failure to reproduce the reference product’s exposure profile. A generic that matches the total daily dose but releases too much methylphenidate during the first few hours may produce a different clinical effect. A product with inadequate late-day release may fail to provide comparable duration.

Excipient changes can be acceptable, but they must not alter performance or introduce safety concerns. FDA’s inactive-ingredient framework evaluates route, dosage form, exposure, and prior use. Novel excipients or materially higher exposure can increase review complexity.[5]

How does Metadate CD compare with competing methylphenidate products?

Metadate CD competes with several release architectures rather than with one uniform product class.

Product type	Release design	Commercial advantage	Formulation challenge
Metadate CD-type bead capsule	Immediate and extended-release beads	Sprinkle administration and flexible bead engineering	Matching biphasic PK
Concerta-type osmotic tablet	Osmotic controlled-release tablet	Long duration and tablet convenience	Device-like delivery system and distinct release profile
Ritalin LA-type bead capsule	Biphasic bead release	Familiar capsule and twice-pulse profile	Maintaining pulse timing
Generic methylphenidate ER capsule	Usually bead-based or equivalent multiparticulate system	Lower price and formulary access	Demonstrating equivalence and consistent supply
Immediate-release methylphenidate	Rapid, short duration	Dose flexibility and low acquisition cost	Multiple daily dosing and adherence burden

The strongest differentiation opportunities are duration, onset, sprinkle usability, taste masking, dose flexibility, and supply reliability. A new product does not need to duplicate every Metadate CD attribute if it can establish a clinically meaningful and regulatorily acceptable delivery profile.

What commercial opportunities exist for excipient suppliers and manufacturers?

Generic and authorized-generic supply

The largest near-term opportunity is supplying generic manufacturers with validated polymer, bead, capsule, and coating systems. Customers are likely to value supply security because methylphenidate products are controlled substances and have experienced periodic availability constraints.

505(b)(2) differentiated products

A 505(b)(2) product could pursue a modified formulation, alternative capsule system, improved sprinkle product, or different duration profile while relying in part on existing methylphenidate data. The commercial case would require a clear advantage over low-cost ANDA products.

Potential claims include:

• Improved palatability.
• Reduced swallowing burden.
• More predictable late-day coverage.
• Reduced food effect.
• Lower variability between patients.
• Alternative dose strengths.
• Improved storage stability.
• Simplified titration.

Licensing and formulation partnerships

The most licensable assets are likely to be:

1. Multiparticulate coating platforms.
2. Taste-masking technologies.
3. High-throughput drug-layering processes.
4. Bead systems with low batch-to-batch variability.
5. Excipient combinations supported by dissolution and PK data.
6. Pediatric delivery platforms compatible with capsules, sachets, or food vehicles.

Broad claims directed only to common excipients are difficult to defend. Stronger protection may arise from a defined combination of polymer ratios, bead-size distributions, coating weight gain, dissolution limits, and pharmacokinetic performance.

What manufacturing and supply-chain barriers affect the opportunity?

Manufacturing complexity is a practical barrier even after patent expiry. Key control points include:

• Drug loading uniformity.
• Bead-size segregation.
• Fluid-bed coating conditions.
• Polymer curing time and temperature.
• Residual solvent and moisture.
• Capsule fill-weight control.
• Content uniformity across strengths.
• Colorant consistency.
• Packaging compatibility.
• Controlled-substance inventory management.

A commercial excipient strategy should qualify at least two sources for critical materials where possible. The qualification package should include compendial compliance, impurity controls, elemental impurities, residual solvents, microbiological limits, change-notification commitments, and supply-continuity terms.

What is the revenue exposure and competitive outlook for Metadate CD?

Metadate CD revenue is not generally disclosed as a standalone product line by its commercial owners. Revenue exposure is therefore best assessed through prescription volume, net price, formulary position, generic substitution, and availability rather than public brand-level sales.

The commercial outlook is structurally defensive:

• Brand pricing faces generic substitution.
• Controlled-substance quotas can constrain both brand and generic supply.
• Pediatric prescribing supports recurring demand.
• Formulary placement can shift volume rapidly.
• Shortages create temporary opportunities for alternate manufacturers.
• A differentiated sprinkle or duration profile can support premium pricing.
• Excipient suppliers can generate recurring revenue without owning the finished product.

Key Takeaways

• Metadate CD is a multiparticulate methylphenidate ER capsule with approximately 30% immediate-release and 70% extended-release drug.
• Its excipient strategy depends on bead substrates, drug-layering binders, controlled-release polymers, plasticizers, anti-tacking agents, and capsule materials.
• The most valuable formulation know-how concerns coating permeability, bead uniformity, dissolution control, and sprinkle performance.
• Original NCE exclusivity has expired, and generic competition is the principal commercial reality.
• Current Orange Book listings and any unexpired patents require product-specific verification before litigation or launch decisions.
• Biosimilar risk is not relevant because methylphenidate hydrochloride is a small molecule.
• Commercial opportunities remain in generic supply, 505(b)(2) differentiated delivery systems, taste masking, coating platforms, and excipient supply agreements.
• Manufacturing capability and controlled-substance supply continuity may be stronger practical barriers than patent protection.

FAQs

Can Metadate CD beads be compressed into a tablet?

Not without redevelopment. Compression can fracture or deform the release-controlling coatings and change dissolution and pharmacokinetics.

Which excipient is most important for Metadate CD release?

The controlled-release polymer system is generally the most important excipient category, but its effect depends on coating weight, plasticizer level, bead size, curing, and process conditions.

Is a methylphenidate ER capsule automatically substitutable for Metadate CD?

No. Substitution depends on FDA approval, therapeutic-equivalence coding, state pharmacy law, and the specific product’s labeled equivalence.

Does Metadate CD have biosimilar competition?

No. Biosimilar regulations apply to biological products. Metadate CD contains the small molecule methylphenidate hydrochloride and is challenged through generic-drug pathways.

What is the best patent strategy for a new Metadate CD-like product?

A stronger strategy combines formulation claims with measurable dissolution, bead-size, coating, stability, and pharmacokinetic limitations. Trade-secret protection for manufacturing parameters should supplement, not replace, patent protection.

References

1. U.S. Food and Drug Administration. (2023). Metadate CD prescribing information. DailyMed.
2. National Library of Medicine. (2024). Metadate CD: Inactive ingredients and product labeling. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Food and Drug Administration. (2024). Small business and industry assistance: Exclusivity and patent provisions.
5. U.S. Food and Drug Administration. (2019). Inactive ingredient database. Center for Drug Evaluation and Research.